Pharmafile Logo
Pharmafocus logo
Advanced Search

lung cancer

Showing 15 posts of 203 posts found.

HUTCHMED completes enrolment in phase 3 trial for lung cancer

August 21, 2025
Research and Development HUTCHMED, Oncology, clinical trial, lung cancer, non-small cell lung cancer

HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use of ORPATHYS (savolitinib) in combination …

News
Lung cancer cells

Graphene-based biosensor to support new lung cancer screening test

August 18, 2025
Business Services, Research and Development Ease Healthcare, Hawkeye Bio, HydroGraph, Oncology, lung cancer

HydroGraph, a Canadian producer of ultra-pure graphene, has announced a partnership with Hawkeye Bio and Ease Healthcare to support the …

News

FDA approves diagnostic tool for MET-targeted lung cancer therapy

May 19, 2025
Research and Development FDA, Oncology, Roche, lung cancer, non-squamous non-small cell lung cancer

The US Food and Drug Administration (FDA) has approved Roche’s VENTANA MET (SP44) RxDx Assay as a diagnostic tool to …

News

Bristol Myers Squibb receives positive CHMP opinion for Opdivo treatment

April 4, 2025
Research and Development CHMP, Oncology, bristol myers squibb, immunotherapy, lung cancer, opdivo

Bristol Myers Squibb (BMS) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for …

News
lung_cancer_on_chest_x-ray

Imidex and Spesana collaborate over impact of AI in lung nodule and mass detection

July 12, 2024
Research and Development Imidex, Oncology, Spesana, artificial intelligence, cancer detection, lung cancer

Personalised medicine technology company Spesana and Imidex, developer of computer-aided detection technology, have announced a strategic partnership to research AI’s …

News

iOnctura expands clinical trial programme for NSCLC

July 9, 2024
Research and Development NSCLC, Oncology, clinical trial, iOnctura, lung cancer

iOnctura has announced the expansion of its clinical trial programme for its lead pipeline asset, roginolisib.

News

AstraZeneca’s Tagrisso gains EU approval for lung cancer treatment

July 8, 2024
Medical Communications AstraZeneca, Oncology, Tagrisso, lung cancer

AstraZeneca has announced that the EU’s European Commission (EC) has approved Tagrisso (osimertinib), with the addition of pemetrexed and platinum-based …

News

AstraZeneca’s Tagrisso approved in Japan for lung cancer treatment

June 25, 2024
Medical Communications AstraZeneca, Oncology, Tagrisso, chemotherapy, lung cancer

AstraZeneca has announced that Tagrisso (osimertinib) in combination with pemetrexed and platinum-based chemotherapy has been approved in Japan for the …

News

CHMP recommends AstraZeneca’s Tagrisso for approval for lung cancer treatment

June 3, 2024
Medical Communications CHMP, EMA, Oncology, Tagrisso, lung cancer

AstraZeneca has announced that Tagrisso (osimertinib) alongside pemetrexed and platinum-based chemotherapy, has been recommended for approval in the EU for …

News

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer

May 17, 2024
Medical Communications Amgen, FDA, Oncology, lung cancer

Amgen has announced that the US Food and Drug Administration (FDA) has approved Imdelltra (tarlatamab-dlle) for the treatment of adult …

News

J&J gains positive CHMP opinion for Rybrevant for treatment of lung cancer

April 29, 2024
Medical Communications CHMP, EMA, J&J, Oncology, Rybrevant, lung cancer

Janssen, a Johnson & Johnson (J&J) company, has announced that the Committee for Medicinal Products for Human Use (CHMP) of …

News

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024
Medical Communications FDA, Oncology, Roche, lung cancer

Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) for the adjuvant treatment following …

News

FDA clears Oryzon’s phase 1/2 trial for lung cancer treatment

April 10, 2024
Research and Development FDA, Oncology, Oryzon, lung cancer

Oryzon Genomics has announced that the US Food and Drug Administration (FDA) has approved its investigational new drug (IND) application …

News

AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer

April 5, 2024
Research and Development AstraZeneca, Imfinzi, Oncology, clinical trial, lung cancer

AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that Imfinzi (durvalumab) had a statistically …

News

Merck completes acquisition of Harpoon Therapeutics for $650m

March 12, 2024
Business Services Harpoon Therapeutics, Merck, Oncology, lung cancer

Merck, known as MSD outside of the US and Canada, has announced that it has completed the acquisition of Harpoon …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025